Literature DB >> 7914148

Adenylyl cyclase activity in Alzheimer's disease brain: stimulatory and inhibitory signal transduction pathways are differently affected.

A Schnecko1, K Witte, J Bohl, T Ohm, B Lemmer.   

Abstract

Adenylyl cyclase (AC) activity was studied in post mortem hippocampus and cerebellum from eight patients with Alzheimer's disease/senile dementia of the Alzheimer type (AD/SDAT) and seven non-demented control patients. AC was stimulated via stimulatory guanine nucleotide binding proteins (Gs) using guanosine triphosphate (GTP) and GppNHp (both 10(-4) M) or directly with either forskolin (10(-4) M) or Mn2+ (10(-2) M). Inhibition of AC via A1-receptors was performed with N6-cyclohexyladenosine (CHA) under basal conditions and in the presence of forskolin (10(-5) M). In both brain regions AC activity was significantly reduced in AD/SDAT when compared to controls. Under basal conditions and after stimulation via Gs mean reduction in hippocampus and cerebellum was 47.7% and 58.2%, respectively. The reduction was less pronounced after direct activation of the AC, amounting to 21.8% in hippocampus and 28.1% in cerebellum. CHA inhibited basal and forskolin-stimulated AC concentration-dependently by about 20% (basal) and 30% (forskolin). Inhibition by CHA was similar in hippocampus and cerebellum and tended to be more pronounced in AD/SDAT than in controls. Since the reduction of AC activity in AD/SDAT is greater after stimulation via Gs than after direct activation of the catalytic subunit, we suggest that both Gs and the catalytic subunit seem to be impaired. The fact that CHA-mediated inhibition of AC is not significantly different in AD/SDAT and controls, indicates that in contrast to Gs-, inhibitory G-proteins (Gi) coupling to AC remains intact in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914148     DOI: 10.1016/0006-8993(94)91692-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits.

Authors:  N Galeotti; C Ghelardini; A Bartolini
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons.

Authors:  J F Kelly; K Furukawa; S W Barger; M R Rengen; R J Mark; E M Blanc; G S Roth; M P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Diminished CRE-Induced Plasticity is Linked to Memory Deficits in Familial Alzheimer's Disease Mice.

Authors:  Nancy Bartolotti; Laura Segura; Orly Lazarov
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 4.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

5.  Ca2+/CaM-sensitive adenylyl cyclase activity is decreased in the Alzheimer's brain: possible relation to type I adenylyl cyclase.

Authors:  M Yamamoto; H Ozawa; T Saito; S Hatta; P Riederer; N Takahata
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

Review 7.  Disturbances in signal transduction mechanisms in Alzheimer's disease.

Authors:  C J Fowler; R F Cowburn; A Garlind; B Winblad; C O'Neill
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

Review 8.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16

Review 9.  Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.

Authors:  Amy J Tibbo; Gonzalo S Tejeda; George S Baillie
Journal:  Biochem Soc Trans       Date:  2019-10-31       Impact factor: 5.407

Review 10.  Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.

Authors:  Carmen Martínez-Cué; Noemí Rueda
Journal:  Int J Mol Sci       Date:  2020-09-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.